CUBRC

CUBRC

学术研究

Buffalo，New York 1,503 位关注者

Advantage Through Technology

查看职位 关注

关于我们

Since CUBRC’s emergence in 1983, the company has grown from a small facilitator of research into a fully staffed, highly respected, scientifically crucial entity. While it is our mission to make a positive technological and economic impact on Western New York, the influences of our work stretch far beyond the WNY region by making significant technology contributions to our nation as a whole. The technologies and facilities of CUBRC date back to the late 1950s, playing a major role in the development and testing of NASA’s Gemini and Apollo space capsules, the U.S. Space Shuttle as well as many other vehicles that travel through Earth’s atmosphere at speeds much greater than that of sound. More recently, CUBRC has continued its pioneering work in the area of aeronautics by expanding and enhancing our Hypervelocity research facilities into a unique research and test capability, available nowhere else in the world. In 1988, CUBRC expanded our technology to reach beyond aeronautics. CUBRC has made tremendous contributions in defending our country against the effects of biological and chemical agents, improving clinical diagnostic instruments that test for diseases, helping to save lives on streets and highways, and helping people make critical decisions through the development of advanced information systems designed to provide crucial information extracted from massive, disparate sources of data. CUBRC offers exciting challenges where ideas and skills are valued and individual contributions are respected, recognized, and rewarded. Continually adapting and expanding, CUBRC remains invested in the power of technology, of first-rate facilities, and of innovative, highly motivated minds to impact and benefit all humankind.

网站
https://www.cubrc.org/
所属行业
学术研究
规模
201-500 人
总部
Buffalo，New York
类型
非营利机构
创立
1983
领域
Research、Aeronautics、Technology Development、Transportation Research、Data Science、Information Fusion、Biology、Chemistry、Software Engineering、Programming、Medical Sciences、Machine Learning、Medical Research和Ontology

地点

CUBRC员工

查看全部员工

动态

  • CUBRC转发了

    查看CUBRC的公司主页，图片
    CUBRC

    1,503 位关注者

    CUBRC, Inc.’s President and CEO, Tom McMahon has announced that CUBRC, in collaboration with EpiVax, Inc., was awarded a two-year contract worth $2 million from the Food and Drug Administration (FDA) within the Department of Health and Human Services (HHS). The goal of this research program is to provide information that helps to?‘frame’ the risk for each generic drug?and may assist drug developers and FDA reviewers to differentiate impurities that are potentially riskier from those that are lower risk. The new FDA-funded collaboration builds on research performed by CUBRC and EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under this newly awarded project, CUBRC and EpiVax will develop standardized controls for T-cell assays performed to?assess the immunogenicity risk?of generic drugs?in support of ANDA applications as outlined in the relevant?FDA guidance. The new contract will?establish new “standards”?that may be used to enhance specificity and sensitivity across industry assay methods for generic drugs, such as such as teriparatide, exenatide, liraglutide and tirzepatide. More information regarding this contract award can be found on our website: https://lnkd.in/gcM2pMHF

  • 查看CUBRC的公司主页，图片
    CUBRC

    1,503 位关注者

    CUBRC, Inc.’s President and CEO, Tom McMahon has announced that CUBRC, in collaboration with EpiVax, Inc., was awarded a two-year contract worth $2 million from the Food and Drug Administration (FDA) within the Department of Health and Human Services (HHS). The goal of this research program is to provide information that helps to?‘frame’ the risk for each generic drug?and may assist drug developers and FDA reviewers to differentiate impurities that are potentially riskier from those that are lower risk. The new FDA-funded collaboration builds on research performed by CUBRC and EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under this newly awarded project, CUBRC and EpiVax will develop standardized controls for T-cell assays performed to?assess the immunogenicity risk?of generic drugs?in support of ANDA applications as outlined in the relevant?FDA guidance. The new contract will?establish new “standards”?that may be used to enhance specificity and sensitivity across industry assay methods for generic drugs, such as such as teriparatide, exenatide, liraglutide and tirzepatide. More information regarding this contract award can be found on our website: https://lnkd.in/gcM2pMHF

  • CUBRC转发了

    查看EpiVax, Inc.的公司主页，图片
    EpiVax, Inc.

    4,987 位关注者

    Breaking news! We’re thrilled to announce that EpiVax and CUBRC have secured a $2 million contract from the FDA’s Office of Generic Drugs (OGD) to develop standardized control peptides for immunogenicity assessment of generic peptide drugs. This project will focus on creating positive and negative controls for T cell assays, supporting ANDA applications for generic peptide drugs such as teriparatide, liraglutide, and tirzepatide, and more. This new FDA-funded collaboration builds on EpiVax’s prior research, which demonstrated the value of in silico and in vitro methods for assessing the immunogenicity risk of generic drug impurities. This included the development of the What-if Machine (WhIM) algorithm to identify and categorize impurities based on their risk level, allowing both drug developers and FDA reviewers to better assess immunogenicity risks. The aim of this latest contract is to establish new “standards” that enhance specificity and sensitivity across industry assay methods. EpiVax looks forward to executing this project in collaboration with CUBRC and continuing to improve access to safe and effective generic peptide drug products by leading in the development of new industry standards for generic peptide drug immunogenicity assessment. Interested in learning more about our research in generic peptides and their impurities, or EpiVax’s PANDA? Approach for immunogenicity risk assessment? We’d love to connect! Read the press release: https://lnkd.in/edP-kFt3 #Immunogenicity #Genericdrugs #ANDA #Peptides

    EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs - EpiVax

    EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs - EpiVax

    https://epivax.com

  • 查看CUBRC的公司主页，图片
    CUBRC

    1,503 位关注者

    CUBRC is proud to be participating in OFCCP's First Annual Veteran Resource & Opportunity Fair. Please feel free to stop by our booth November 6th (11am-2pm) at WNY Heroes and talk with our representatives and ask any questions you may have.

  • CUBRC转发了

    查看CUBRC的公司主页，图片
    CUBRC

    1,503 位关注者

    CUBRC is excited to announce that it has acquired Ahmic Aerospace. Ahmic is a rapidly growing Dayton, OH based company that specializes in developing and manufacturing high-performance instrumentation and measurement techniques. We're excited to have the Ahmic team join the CUBRC family! Please see the media release below for additional information. #flyfast #cubrc #hypersonic

    • 该图片无替代文字
  • 查看CUBRC的公司主页，图片
    CUBRC

    1,503 位关注者

    CUBRC is excited to announce that it has acquired Ahmic Aerospace. Ahmic is a rapidly growing Dayton, OH based company that specializes in developing and manufacturing high-performance instrumentation and measurement techniques. We're excited to have the Ahmic team join the CUBRC family! Please see the media release below for additional information. #flyfast #cubrc #hypersonic

    • 该图片无替代文字

相似主页

查看职位